Advanced kidney cancer
Trovati 15 articoli
- Acute myeloid leukemia: Nexavar targets a genetic mutation active in about one third of patients
- A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia ( AML ), the most common and lethal form of adult leukemia, researchers at The University of Texas MD Anderson Cancer Center reported in the Journal of the National... (Leggi Articolo)
- Hepatocellular carcinoma: Nexavar significantly prolongs overall survival
- Sorafenib ( Nexavar ) tablets has significantly extended overall survival in patients with hepatocellular carcinoma ( HCC ), or primary liver cancer versus those taking placebo by 44% ( HR=0.69; p-value=0.0006 ). The Phase 3, placebo-controlled Sorafenib HCC Assessment Randomized Protocol ( SH... (Leggi Articolo)
- FDA has strengthened boxed warnings for erythropoiesis-stimulating agents
- The FDA ( Food and Drug Administration ) has approved revised boxed warnings and other safety-related product labeling changes for erythropoiesis-stimulating agents ( ESAs ), which treat certain types of anemia. These new statements address the risks that the drugs Aranesp ( Darbepoetin alpha ), ... (Leggi Articolo)
- Advanced renal cell carcinoma: Temsirolimus improves overall survival
- The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show Temsirolimus ( Torisel ) improved overall survival when compared to the current treatment for this stage of disease. The study was led by Gary R. Hudes, a... (Leggi Articolo)
- Inoperable hepatocellular carcinoma: FDA has approved Nexavar
- The FDA ( Food and Drug Administration ) has approved Nexavar ( Sorafenib ) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma,... (Leggi Articolo)
- A subset of kidney cancer patients responds well to an experimental drug CCI-779
- Researchers at UCLA ( University of California - Los Angeles ) knew - based on two clinical trials - that a subset of kidney cancer patients responded well to an experimental targeted therapy, but they didn't know why. If they could determine the mechanism behind the response, they would be abl... (Leggi Articolo)
- A subset of kidney cancer patients responds well to an experimental drug CCI-779
- Researchers at UCLA ( University of California - Los Angeles ) knew - based on two clinical trials - that a subset of kidney cancer patients responded well to an experimental targeted therapy, but they didn't know why. If they could determine the mechanism behind the response, they would be abl... (Leggi Articolo)
- A subset of kidney cancer patients responds well to an experimental drug CCI-779
- Researchers at UCLA ( University of California - Los Angeles ) knew - based on two clinical trials - that a subset of kidney cancer patients responded well to an experimental targeted therapy, but they didn't know why. If they could determine the mechanism behind the response, they would be abl... (Leggi Articolo)
- Advanced kidney cancer: Sutent shows significant benefits over Interferon-alpha
- Sunitinib ( Sutent ) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma ( mRCC ). " Sunitinib has shown more activity as a single agent against advanced kidney cancer... (Leggi Articolo)
- FDA has approved Sutent in GIST and advanced kidney cancer
- The FDA ( Food and Drug Administration ) announced approval of Sutent ( Sunitinib ), a new targeted anti-cancer treatment for patients with gastrointestinal stromal tumors ( GIST ), a rare stomach cancer, and advanced kidney cancer. Sutent is a tyrosine kinase inhibitor working through multip... (Leggi Articolo)
- Efficacy and safety of Sunitinib in previously treated, advanced non-small cell lung cancer
- A phase II study is assessing the safety and efficacy of Sunitinib ( Sutent ) in patients with advanced non-small cell lung cancer ( NSCLC ) that had progressed following standard therapy. “ This is the first clinical trial to evaluate Sunitinib alone in advanced lung cancer patients for who... (Leggi Articolo)
- Cancer: Cetuximab shows promise
- The results of several clinical studies of Cetuximab ( Erbitux ) have been presented at the American Society of Clinical Oncology ( ASCO ) 41st Annual Meeting. Irinotecan-refractory metastatic colorectal cancer Findings were presented of a randomized Phase II trial conducted by the Natio... (Leggi Articolo)
- Bladder cancer, recognizing the early warning signs
- Bladder cancer occurs about three times more often in men than women. It’s also more likely to strike older adults. Environmental factors such as tobacco and industrial chemicals can increase the risk of bladder cancer as well. Chemicals such as industrial solvents, paints and paint thinners ... (Leggi Articolo)
- Combination of Interleukin-12 and Interferon appears to be safe
- A research has shown that the immune-stimulating hormone known as Interleukin-12 ( IL-12 ) can safely be administered with Interferon, another immune-system protein, as an experimental therapy for some cancers. Normally, Interferon is used alone to stimulate the immune system to attack certai... (Leggi Articolo)
- Interleukin-12 can safely be administered with Interferon as an experimental therapy for some cancers
- A study has shown that the immune-stimulating hormone known as Interleukin-12 ( IL-12 ) can safely be administered with Interferon, another immune-system protein, as an experimental therapy for some cancers. Normally, Interferon is used alone to stimulate the immune system to attack certain c... (Leggi Articolo)
